PreSCD II Registry Shows ICDs Lead To 44 Percent Reduction In Mortality For Heart Attack Survivors

Boston Scientific Corporation (NYSE: BSX) announced long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II). The results found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality (p=0.053) when implanted in patients following myocardial infarction (heart attack). The mortality reduction trend was also observed in high-risk patients with severely reduced heart function.